Pre-made Acapatamab benchmark antibody ( Bispecific scFv, anti-FOLH1;CD3E therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-006
Anti-FOLH1;CD3E therapeutic antibody (Pre-made Acapatamab biosimilar,Bispecific scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Acapatamab (formerly AMG 160) is a half-life extended (HLE) anti- prostate-specific membrane antigen (PSMA) x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated for the treatment of non-small cell lung cancer (NSCLC).
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-FOLH1;CD3E therapeutic antibody (Pre-made Acapatamab biosimilar,Bispecific scFv)|
|Highest_Clin_Trial (Jan '20)||Phase-I/II|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||None;None|
|Conditions Active||Cancers;Prostrate cancer;Metastatic cancer|
|Development Tech||BiTE Technology|